Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
23 nov. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four...
TeneoFour’s CD38 Inhibitor Rejuvenates Energy Metabolism of Aged Animals
16 nov. 2020 11h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoFour, Inc. announced today a Nature Metabolism publication...
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
21 oct. 2020 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...
Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma
06 nov. 2019 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
08 janv. 2018 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and...
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy
22 mai 2017 08h00 HE
|
TeneoBio, Inc
MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of...